Vaccine PRIORIX TETRA – (2,420) at Dr. Essa Lab

Vaccine PRIORIX TETRA – (2,420) at Dr. Essa Lab

Vaccine PRIORIX TETRA – (2,420) is a highly advanced, combined live attenuated vaccine designed to provide active immunization against four major childhood viral diseases: Measles, Mumps, Rubella, and Varicella (chickenpox). Administered under strict clinical guidelines at Dr. Essa Lab, this vaccine plays a pivotal role in pediatric preventive medicine and public health. By combining protection against these four highly contagious pathogens into a single injection, Vaccine PRIORIX TETRA – (2,420) significantly reduces the number of clinical visits, minimizes pediatric distress, and improves overall compliance with national and international immunization schedules. The vaccine works by introducing weakened (attenuated) strains of the measles virus (Schwarz strain), mumps virus (RIT 4385 strain), rubella virus (Wistar RA 27/3 strain), and varicella-zoster virus (Oka strain) into the body. These attenuated viruses are incapable of causing the actual diseases in healthy individuals but are highly effective at stimulating the host immune system to produce specific neutralizing antibodies (Immunoglobulin G or IgG) and establish long-term immunological memory.

At Dr. Essa Lab, we recognize that maintaining the integrity of live vaccines is of paramount importance. The clinical value of Vaccine PRIORIX TETRA – (2,420) relies heavily on a flawless cold chain system, which we maintain rigorously from storage to administration. The anatomical target of this vaccine is the systemic immune system, specifically the lymphatic network, where antigen-presenting cells process the viral antigens and trigger the proliferation of protective T and B lymphocytes. This comprehensive vaccine is indicated for children from 11 months up to 12 years of age, offering a robust defense against severe viral complications such as pneumonia, encephalitis, congenital rubella syndrome, and secondary bacterial skin infections. Choosing Dr. Essa Lab for your child’s immunization ensures that the vaccine is stored, reconstituted, and administered according to the highest international medical standards.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure the safety and efficacy of Vaccine PRIORIX TETRA – (2,420). Parents and guardians should follow these medically recommended preparation guidelines before visiting Dr. Essa Lab:

• Medical History Review: Inform the healthcare provider of any known allergies, especially severe allergic reactions to neomycin, gelatin, or any other component of the vaccine.
• Health Assessment: Ensure the child does not have a high-grade fever or acute moderate-to-severe illness on the day of vaccination. Mild infections, such as a common cold, are generally not contraindications, but a clinical assessment is advised.
• Immunodeficiency Disclosure: Disclose if the child has a compromised immune system due to conditions like leukemia, lymphoma, HIV/AIDS, or is undergoing immunosuppressive therapies (such as high-dose systemic corticosteroids or chemotherapy).
• Blood Products and Immunoglobulins: Inform the doctor if the child has received a blood transfusion or human immunoglobulin administration within the past three to eleven months, as these can interfere with the immune response to live vaccines.
• Pregnancy Status: While primarily a pediatric vaccine, if administered to adolescents, pregnancy must be ruled out, and pregnancy should be avoided for at least one month following vaccination.
• Vaccination Records: Bring the child’s complete immunization card or previous vaccination history to help the clinician determine the correct dosing interval.

During the Procedure

The administration of Vaccine PRIORIX TETRA – (2,420) at Dr. Essa Lab follows a standardized, sterile clinical protocol to ensure patient safety and comfort:

• Verification and Reconstitution: The clinical nurse verifies the vaccine’s expiration date, batch number, and cold chain status. The lyophilized powder is reconstituted using the sterile solvent provided by the manufacturer immediately before injection.
• Patient Positioning: The child is positioned comfortably, usually held securely by a parent or guardian. Infants are typically vaccinated in the anterolateral thigh, while older children receive the injection in the deltoid region of the upper arm.
• Aseptic Technique: The injection site is thoroughly cleansed with an alcohol swab and allowed to dry completely to prevent inactivation of the live virus by the disinfectant.
• Injection Administration: The vaccine is administered subcutaneously (SC) or intramuscularly (IM) at a 45-degree or 90-degree angle, depending on the chosen route and the child’s muscle mass.
• Post-Vaccination Observation: After the injection, a small sterile dressing is applied to the site. The patient is required to remain in the waiting area under clinical observation for 15 to 30 minutes to monitor for any immediate, rare allergic reactions (anaphylaxis).

When is a Vaccine PRIORIX TETRA – (2,420) Performed?

Routine Childhood Immunization Schedule

Physicians recommend Vaccine PRIORIX TETRA – (2,420) as part of the primary pediatric immunization schedule. It is typically administered in a two-dose series to ensure complete seroconversion. The first dose is commonly given between 11 and 12 months of age, and the second dose is administered between 15 and 18 months of age, or prior to school entry, to provide long-lasting immunity against all four target viruses.

Prevention of Measles, Mumps, and Rubella Outbreaks

In regions where measles, mumps, or rubella remain endemic, or during active community outbreaks, healthcare providers prioritize this combined vaccine. Measles is highly contagious and can lead to severe respiratory and neurological complications; prompt vaccination of eligible children helps establish robust herd immunity and curtails transmission.

Varicella (Chickenpox) Prophylaxis

Varicella can cause severe systemic illness, particularly in older children and adolescents, leading to painful vesicular rashes, high fever, and risk of secondary bacterial superinfections. Physicians prescribe Vaccine PRIORIX TETRA – (2,420) to prevent primary varicella infection and its associated complications, such as cerebellar ataxia or varicella pneumonitis.

Catch-Up Vaccination for Eligible Children

For children up to 12 years of age who missed their scheduled individual MMR or varicella vaccines, Vaccine PRIORIX TETRA – (2,420) serves as an efficient catch-up option. It allows healthcare providers to close the immunity gap quickly, ensuring the child is fully protected against all four pathogens with fewer injections.

Pre-Travel Immunization for High-Risk Areas

Families planning international travel to countries with high prevalence rates of measles, mumps, rubella, or chickenpox are advised to secure vaccination beforehand. Pediatricians recommend administering Vaccine PRIORIX TETRA – (2,420) at least several weeks prior to departure to allow the child’s immune system to develop protective antibody levels.

What Does a Vaccine PRIORIX TETRA – (2,420) Detect?

While Vaccine PRIORIX TETRA – (2,420) is a preventive immunization rather than a diagnostic test, it induces specific physiological responses and immunological markers that can be clinically evaluated. The administration of this vaccine is designed to achieve, stimulate, and prevent the following clinical parameters:

• Measles IgG Seroconversion: Stimulates the production of protective Immunoglobulin G antibodies against the measles virus, typically achieving seroconversion in over 98% of vaccinees.
• Mumps IgG Seroconversion: Induces specific neutralizing antibodies against the mumps virus to prevent parotitis and systemic complications.
• Rubella IgG Seroconversion: Promotes high levels of rubella-specific antibodies, ensuring long-term protection and preventing future risks of congenital rubella syndrome.
• Varicella-Zoster Virus (VZV) Antibodies: Elicits humoral and cellular immune responses against VZV, significantly reducing the risk of chickenpox and shingles later in life.
• Active Immunization Status: Establishes a documented state of active immunity, which can be verified via post-vaccination serology if clinically indicated.
• Immunological Memory: Stimulates the generation of memory B lymphocytes and T lymphocytes, enabling a rapid secondary immune response upon future exposure to wild-type viruses.
• Prevention of Measles-Induced Immune Amnesia: Protects the child’s existing immune repertoire by preventing wild measles infection, which is known to erase pre-existing immunological memory.
• Reduction in Subacute Sclerosing Panencephalitis (SSPE) Risk: Virtually eliminates the risk of SSPE, a fatal progressive neurological disorder caused by persistent measles virus infection.
• Prevention of Mumps Orchitis: Protects post-pubertal males from mumps-induced testicular inflammation, which can lead to subfertility or infertility.
• Prevention of Mumps Aseptic Meningitis: Significantly decreases the incidence of viral meningitis associated with wild mumps infection.
• Prevention of Congenital Rubella Syndrome (CRS): Indirectly protects future generations by ensuring females are immune to rubella before reaching childbearing age.
• Prevention of Varicella Pneumonitis: Prevents severe viral lung infections, which are a major cause of morbidity in older children contracting chickenpox.
• Reduction of Secondary Bacterial Infections: By preventing varicella vesicles, it reduces the risk of secondary skin infections caused by Staphylococcus aureus or Streptococcus pyogenes.
• Prevention of Cerebellar Ataxia: Protects against neurological complications of chickenpox, such as acute cerebellar ataxia.
• Herd Immunity Contribution: Increases community protection levels, safeguarding vulnerable individuals who cannot be vaccinated due to medical contraindications.
• Reduction in Pediatric Hospitalizations: Lowers the rate of emergency room visits and hospital admissions related to vaccine-preventable viral syndromes.
• Prevention of Viral-Induced Thrombocytopenia: Minimizes the risk of transient thrombocytopenic purpura, a known complication of natural measles and rubella infections.
• Long-Term Cost-Effectiveness: Reduces the healthcare burden and parental work absenteeism associated with caring for children suffering from prolonged viral illnesses.
• Safe Co-Administration Profile: Demonstrates compatible safety and immunogenicity when administered concurrently with other routine childhood vaccines.
• Minimization of Injection-Related Distress: Combines four essential antigens into a single dose, reducing pediatric needle phobia and physical trauma.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we ensure that your child’s immunization records are processed and documented with the utmost efficiency. Immediately following the administration of Vaccine PRIORIX TETRA – (2,420), our clinical staff will update your physical vaccination card with the vaccine’s batch number, manufacturer details, date of administration, and the recommended date for the next dose. Simultaneously, this information is uploaded directly into our secure digital database. Parents can access their child’s complete immunization history and official vaccination certificates online through the Dr. Essa Lab web portal or via our dedicated mobile application. This digital record serves as a permanent, easily accessible proof of immunization required for school admissions, international travel, and routine pediatric consultations.

Vaccine PRIORIX TETRA – (2,420) Findings Overview

The following table outlines the expected physiological responses, normal clinical findings, and potential abnormal reactions associated with the administration of Vaccine PRIORIX TETRA – (2,420):

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Measles Antibody Response (IgG)	Seropositive (Protective antibody levels detected)	Seronegative (Lack of protective antibodies; potential vaccine failure)
Mumps Antibody Response (IgG)	Seropositive (Protective antibody levels detected)	Seronegative (Lack of protective antibodies; potential vaccine failure)
Rubella Antibody Response (IgG)	Seropositive (Protective antibody levels detected)	Seronegative (Lack of protective antibodies; potential vaccine failure)
Varicella Antibody Response (IgG)	Seropositive (Protective antibody levels detected)	Seronegative (Lack of protective antibodies; potential vaccine failure)
Injection Site Reaction	Mild, transient redness, minor swelling, or localized tenderness resolving within 48 hours	Severe local inflammation, persistent pain, abscess formation, or secondary bacterial infection
Post-Vaccine Temperature	Normal body temperature or mild, transient low-grade fever (usually occurring 5-12 days post-vaccine)	High-grade fever (above 39°C) or febrile convulsions (extremely rare)
Post-Vaccine Skin Assessment	Clear skin or a mild, sparse, non-contagious varicella-like rash (fewer than 10 papules)	Diffuse, severe vesicular rash, generalized urticaria, or immediate allergic dermatitis
Systemic Allergic Response	No immediate hypersensitivity or allergic symptoms	Acute anaphylaxis, bronchospasm, facial angioedema (requires immediate emergency medical intervention)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Vaccine PRIORIX TETRA – (2,420)?

• Experienced Healthcare Professionals: Our clinical staff and pediatric nurses are highly trained in gentle, accurate, and safe vaccine administration techniques for infants and children.
• Strict Cold Chain Management: We utilize state-of-the-art refrigeration systems and continuous temperature monitoring to guarantee that the Vaccine PRIORIX TETRA – (2,420) remains potent and effective.
• Patient-Focused Care: We prioritize a compassionate, child-friendly environment to minimize anxiety and make the vaccination experience as comfortable as possible for both parents and children.
• ISO Certified Quality Standards: Dr. Essa Lab operates under rigorous quality control protocols, ensuring international standards of safety, hygiene, and clinical excellence.
• Convenient Digital Records: Access your child’s immunization history, certificates, and future vaccine reminders seamlessly through our secure online portal and mobile app.
• Extensive Branch Network: With numerous convenient locations across Karachi and other major cities, accessing premium healthcare and vaccination services is always within reach.
• Comprehensive Diagnostic Services: From routine pediatric blood tests to advanced imaging, Dr. Essa Lab offers a complete suite of diagnostic services under one roof.
• Trusted Legacy of Excellence: Serving the community since 1987, Dr. Essa Lab is one of Pakistan’s most respected and trusted names in diagnostic and preventive healthcare.